Abstract 67: An integrated copy number and gene expression genomics analysis and RNAi approach identifies and validates the KIFC1 kinesin as a malignant cell selective target in triple negative breast cancer
Nirmesh Patel(King's College London), Andrew Tutt(Institute of Cancer Research), Hasan Mirza(London Cancer), Rebecca Marlow(Institute of Cancer Research), Patrycja Gazińska(London Cancer), Elodie Noël(Queen Mary University of London), Jelmar Quist(King's College London), Spiros Linardopoulos(Abzena (United Kingdom)), Erika Francesch Domenech(King's College London), Emanuele de Rinaldis(Target (United States)), Κωνσταντίνος Δροσόπουλος(University of Patras), Daniel Weekes(King's College London), Farzana Noor(King's College London), Mamunur Rashid(National Institute of Cardiovascular Diseases), Sumi Mathew(King's College London), Anita Grigoriadis(London Cancer), Fara Brasó‐Maristany(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k